GlassScriptPhysician profile
Michael Scott Solomon
NPI 1891736633
$11,548.23
in general payments reported to CMS, 2019-2025
18 companies · $693 in 2025
The $693 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,808 · 2020: $172 · 2021: $760 · 2022: $2,871 · 2023: $4,628 · 2024: $616 · 2025: $693.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,485 · Food and Beverage: $2,276 · Entertainment: $88.18 · Education: $87.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,485.40 |
| Food and Beverage | $2,275.79 |
| Entertainment | $88.18 |
| Education | $87.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $4,382.02 | 2022-2025 | |
| Alcon Vision LLC | $1,621.44 | 2019-2025 | Hydrus Microstent, Clareon, Clareon Panoptix Pro |
| Carl Zeiss Meditec USA, INC. | $1,115.28 | 2021-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $838.13 | 2019 | |
| Abbvie INC. | $746.49 | 2022-2024 | Durysta, Xen Glaucoma Treatment System, Botox |
| Carl Zeiss Meditec, INC. | $660.00 | 2022 | |
| Mallinckrodt Hospital Products INC. | $575.43 | 2022-2025 | Acthar |
| Rxsight INC | $366.70 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $269.54 | 2021-2022 | |
| Ivantis, INC | $251.84 | 2020-2021 | |
| Inari Medical, INC. | $195.35 | 2022 | |
| Ocular Therapeutix, INC. | $123.20 | 2024 | Dextenza |
| Kala Pharmaceuticals, INC. | $122.35 | 2021 | |
| Optos, INC. | $88.18 | 2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| New World Medical,INC. | $81.82 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $72.42 | 2021-2023 | Tepezza |
| Allergan, INC. | $19.41 | 2020 | |
| Amgen INC. | $18.63 | 2025 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Solomon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.